Co-Diagnostics announced that its Indian joint venture, CoSara Diagnostics Pvt. Ltd., has signed an agreement to expand its commercial and distribution territory across South Asia to include Bangladesh, Pakistan, Nepal and Sri Lanka. This expansion significantly increases the company's addressable market to an estimated $13.0 billion, according to the announcement.
The territorial expansion supports planned commercialization of the CoSara PCR Pro point-of-care platform and SARAGENE product line, subject to regulatory approvals. The company is building regional distribution channels and positioning for broader deployment of its molecular diagnostics solutions across the newly added countries.
This expansion represents a strategic move to increase access to molecular diagnostics technology in South Asia, where healthcare infrastructure varies significantly across nations. The CoSara PCR Pro platform is designed for point-of-care use, potentially bringing advanced diagnostic capabilities closer to patients in regions where centralized laboratory facilities may be limited.
The SARAGENE product line represents the company's molecular diagnostics technologies designed for detection and analysis of nucleic acid molecules, including DNA or RNA. These technologies form the basis for tests that can identify infectious diseases and other conditions through genetic markers.
Co-Diagnostics also utilizes its proprietary technology to design specific tests for its Co-Dx PCR at-home and point-of-care platform, though these are subject to regulatory review and are not currently for sale. The company's technology has applications beyond infectious disease, including identification of genetic markers for various medical conditions.
The expansion comes as molecular diagnostics continue to play an increasingly important role in global healthcare, particularly following the COVID-19 pandemic which highlighted the importance of rapid, accurate diagnostic testing. The South Asian region, with its combined population of over 1.8 billion people across the newly added countries, represents a significant market opportunity for advanced diagnostic solutions.
For more information about Co-Diagnostics' technology and platforms, visit https://co-dx.com/. The company's forward-looking statements involve risks and uncertainties, including factors beyond management's control as detailed in their SEC filings available through http://IBN.fm/Disclaimer.
